Vistogard® (uridine triacetate) fights toxicity so you can continue fighting your cancer 1-3, 21-23

Vistogard® is the first and only antidote to treat 5-FU or capecitabine toxicity 1, 2, 19

  • 130 of 135 (96%) patients in clinical trials survived severe 5-FU or capecitabine toxicity1 1,2
  • 98% of patients survived when treated with Vistogard® within 96 hours of ending their 5-FU or capecitabine chemotherapy 1, 2
  • One-third of study patients continued chemotherapy within a month after treatment with
    Vistogard® 1, 2

*Survival was 96% among all patients treated with Vistogard® for either early-onset severe toxicity or overdose †16% survival was shown in historical case reports of 5-FU overdose 1, 2, 19

Vistogard® is proven safe and tolerable for patients 1, 2, 19

  • The most common side effects from Vistogard® use in 135 patients enrolled in clinical studies were:
    • Vomiting (10% of patients)
    • Nausea (5% of patients)
    • Diarrhea (3% of patients)
  • The effects of Vistogard® don’t depend on patient’s gender or age
  • Of the 135 patients in clinical studies with Vistogard®, 30% were 65 years of age or older and 11% were 75 years of age or older
  • In the clinical studies, one patient receiving Vistogard® had serious nausea and vomiting
  • Two patients (1.4% of those in clinical trials) discontinued Vistogard® due to side effects related to treatment